FDA approves first genetic test to assess opioid addiction risk using DNA sample
Fox News
The U.S. Food and Drug Administration has approved AvertD, the first test designed to assess the risk of opioid use addiction in specific individuals, officials say.
AvertD is intended to be used before the first use of oral opioid painkillers in those who are being considered for a 4 to 30 days prescription for the treatment of acute pain, such as in patients scheduled to undergo a planned surgical procedure.
More Related News